2seventy bio, Inc. (TSVT) Stock Analysis & Investment Frameworks
2seventy bio, Inc. (TSVT) stock analysis on Invetso. Review 2seventy bio, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
2seventy bio, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
2seventy bio, Inc. Key Financial Metrics
- Market Cap: $266.14M
- Revenue: $37.86M
- ROE: -24.56%
- ROIC: -25.33%
- Dividend Yield: N/A
About 2seventy bio, Inc.
2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma. The company also maintains a strategic partnership with Bristol-Myers Squibb Company. Founded in 2021, its corporate headquarters are situated in Cambridge, Massachusetts.
2seventy bio, Inc. Investment Frameworks
Invetso analyzes 2seventy bio, Inc. (TSVT) across the following frameworks:
- 2seventy bio, Inc. 10Y Growth Potential
- 2seventy bio, Inc. Scenario Analysis
- 2seventy bio, Inc. Risks & Opportunities
- 2seventy bio, Inc. Economic Moat
- 2seventy bio, Inc. Business Model
- 2seventy bio, Inc. Management
- 2seventy bio, Inc. SWOT Analysis
- 2seventy bio, Inc. Porter's 5 Forces
- 2seventy bio, Inc. PESTLE Analysis
- 2seventy bio, Inc. ESG Analysis